| Description | Crovalimab (SKY59; RO7112689) is a novel humanized antibody designed to target C5 in a pH-dependent manner, demonstrating binding affinities (KD) of 15.2 nM and 16.8 μM at pH levels of 7.4 and 5.8, respectively. Additionally, it shows high affinity for human FcRn at pH 6.0, with a KD of 17 μM. By blocking C5 cleavage by C5 convertase and inhibiting the activity of a C5 variant (p.Arg885His), Crovalimab effectively prevents the formation of C5b-9 across the classical (CP), lectin (LP), and alternative (AP) complement pathways. This characteristic highlights its potential utility in research concerning paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases. |
| molecular weight | N/A |
| CAS | 1917321-26-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |